Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies.

ABSTRACT:

Introduction

Migraine is associated with substantial functional impairment and affects many aspects of daily life.

Methods

Using data from SAMURAI and SPARTAN (double-blind, placebo-controlled, phase 3 studies) and GLADIATOR (an open-label, phase 3 study enrolling patients who had completed SAMURAI or SPARTAN), we assessed the effects of lasmiditan on migraine-related functional disability at multiple time points from 0.5 to 48 h post dose by asking patients to rate how much the migraine was interfering with normal activities. Pooled data from SAMURAI and SPARTAN (SAMURAI + SPARTAN) and data from GLADIATOR were analyzed using the intention-to-treat populations.

Results

For SPARTAN + SAMURAI, significantly more patients who received lasmiditan at any dose versus placeb

SUBMITTER: Smith T 

PROVIDER: S-EPMC7606429 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature